Coagulation cascade and platelet activation machinery

The coagulation cascade and platelet activation machinery constitute the primary physiological system for hemostasis, ensuring blood remains fluid within vessels while allowing for rapid clot formation at sites of vascular injury (Palta et al., 2014, StatPearls [https://www.ncbi.nlm.nih.gov/books/NBK482253/]). The coagulation cascade is a series of enzymatic reactions involving serine proteases (clotting factors) that culminate in the conversion of fibrinogen to fibrin, creating a stable meshwork (NIH, 2023 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260295/]). Simultaneously, platelet activation involves the recruitment, adhesion, and aggregation of platelets, mediated by various receptors and signaling molecules like thromboxane A2 and ADP (Gremmel et al., 2016, Nature Reviews Cardiology [https://www.nature.com/articles/nrcardio.2015.171]). Dysregulation of this system is a central driver of cardiovascular diseases, including myocardial infarction and stroke, as well as venous thromboembolism (AHA, 2021 [https://www.ahajournals.org/doi/10.1161/CIR.0000000000001052]). Pharmacological intervention typically targets specific components of this machinery, such as Factor Xa, thrombin, or platelet receptors, to prevent pathological thrombosis while balancing the inherent risk of bleeding (PubChem, 2024 [https://pubchem.ncbi.nlm.nih.gov/compound/Warfarin]).

Other names

Hemostatic systemBlood clotting pathwayThrombotic machineryHemostasis and thrombosis system

Drugs targeting this system operate through several distinct mechanisms: Vitamin K antagonists (e.g., Warfarin) inhibit the synthesis of factors II, VII, IX, and X; Direct Oral Anticoagulants (DOACs) like Rivaroxaban and Apixaban directly inhibit Factor Xa, while Dabigatran inhibits Thrombin (Factor IIa) (FDA, 2023 [https://www.accessdata.fda.gov/scripts/cder/daf/]). Antiplatelet agents like Aspirin irreversibly inhibit COX-1 to prevent thromboxane A2 production, while P2Y12 inhibitors (e.g., Clopidogrel, Ticagrelor) block ADP-mediated activation (Gremmel et al., 2016 [https://www.nature.com/articles/nrcardio.2015.171]). Fibrinolytics like Alteplase catalyze the conversion of plasminogen to plasmin to dissolve existing clots (StatPearls, 2024 [https://www.ncbi.nlm.nih.gov/books/NBK493179/]).